Search
Washed Microbiota Transplantation
go.drugbank.com/drugs/DB15745InvestigationalThe resulting suspension is shown to decrease FMT-related adverse events. … Fecal microbiota transplantation (FMT) is effective in enhancing the gut microbiota of patients experiencing a high range of disease states, including Clostridioides difficile (C. diff) infection, Crohn
Nicomorphine
go.drugbank.com/drugs/DB13454ExperimentalCategories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeAVXS-301
go.drugbank.com/drugs/DB17943ExperimentalAVXS-301 consists of an adeno-associated virus serotype 9 (AAV9) designed to express the superoxide dismutase 1 (SOD1) gene. … It is being investigated for the treatment of Amyotrophic Lateral Sclerosis (ALS).[L47077]
AI-850
go.drugbank.com/drugs/DB05842ExperimentalAI-850 is a Cremophor(R)-free formulation of paclitaxel, the active ingredient in Taxol(R), a product used to treat a variety of solid tumors.
Nendratareotide uzatansine
go.drugbank.com/drugs/DB18351InvestigationalNendratareotide uzatansine is a peptide-drug conjugate comprising a peptide analog of somatostatin conjugated to the cytotoxin mertansine.
Rebamipide
go.drugbank.com/drugs/DB11656ApprovedInvestigationalRebamipide has been investigated for the treatment of Stomach Ulcer, Keratoconjunctivitis Sicca, and Gastric Adenoma and Early Gastric Cancer.
Orismilast
go.drugbank.com/drugs/DB19042InvestigationalOrismilast is under investigation in clinical trial NCT05190419 (Study to Assess the Efficacy and Safety of Orismilast in Psoriasis).
Mirococept
go.drugbank.com/drugs/DB06492ExperimentalIt is a truncated form of the human Complement Receptor 1 (CR1) linked to a unique Prodaptin™ construct that regulates the over-production of complement at the cell surface, which occurs in inflammation … It consists of the first three short consensus domains of human complement receptor 1 (CR1), manufactured in recombinant bacteria and modified with a membrane-targeting amphiphilic peptide based on the
S-8510
go.drugbank.com/drugs/DB06504ExperimentalS-8510 / SB-737552 is a BZD inverse agonist investigated for the treatment of Alzheimer’s disease and mild to moderate senile dementia. It was being codeveloped by Shionogi and GlaxoSmithKline.
Galactose-uridine-5'-diphosphate
go.drugbank.com/drugs/DB03501ExperimentalA nucleoside diphosphate sugar which can be epimerized into UDPglucose for entry into the mainstream of carbohydrate metabolism. … Serves as a source of galactose in the synthesis of lipopolysaccharides, cerebrosides, and lactose.